What is the recommended diagnostic workup and treatment plan for functional diarrhea?

Functional Diarrhea: Diagnostic Workup and Treatment

For functional diarrhea, perform targeted laboratory testing including celiac serology (IgA-tTG with total IgA), Giardia testing, and fecal calprotectin, followed by empiric treatment with lifestyle modifications and loperamide as first-line therapy. 1

Diagnostic Workup Algorithm

Essential Laboratory Tests (Strong Evidence)

The 2019 AGA guidelines provide clear direction on which tests to order:

Mandatory testing for all patients:

• Celiac disease screening: IgA tissue transglutaminase (IgA-tTG) plus total IgA level (strong recommendation, moderate-quality evidence). If IgA-deficient, use IgG-tTG or IgG/IgA deaminated gliadin peptides. Sensitivity and specificity both exceed 90% at thresholds of 7-15 AU/mL. Positive results require duodenal biopsy confirmation. 1

• Giardia testing: Stool antigen test (strong recommendation, high-quality evidence). This is the only parasite test recommended for patients without travel history to high-risk areas. 1

• IBD screening: Fecal calprotectin OR fecal lactoferrin (conditional recommendation, low-quality evidence). Do NOT use ESR or CRP for IBD screening—these have poor diagnostic accuracy. 1

Consider testing for:

• Bile acid diarrhea (conditional recommendation, low-quality evidence): In the U.S., options include 48-hour stool bile acid collection or serum FGF-19. However, given limited test availability, an empiric trial of bile acid sequestrants (cholestyramine, colesevelam) is reasonable and often more practical—clinical response confirms the diagnosis. 1

When to Perform Endoscopy

Colonoscopy with random biopsies from right and left colon is indicated for:

• Age ≥45-50 years
• Alarm features: GI bleeding, unexplained weight loss, iron deficiency anemia, nocturnal diarrhea, steatorrhea
• Refractory symptoms despite treatment

Random biopsies are critical to detect microscopic colitis, which affects 13% of chronic diarrhea patients and appears endoscopically normal. 2, 3

Tests NOT Recommended

• Serologic IBS biomarkers (anti-CdtB, anti-vinculin): No recommendation due to poor sensitivity (20-40%) despite reasonable specificity. These lack diagnostic accuracy for routine use. 1

• Routine ova and parasite testing: Not recommended without travel history to endemic areas (conditional recommendation). 1

Treatment Approach

First-Line: Lifestyle and Dietary Modifications

Specific lifestyle interventions:

• Regularly scheduled meals
• Exercise program
• Minimum 8 cups of non-caffeinated fluids daily
• Limit caffeine to ≤3 cups daily
• Avoid alcohol and carbonated beverages

Dietary approach:

• Low FODMAP diet (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) has strong evidence, improving symptoms in 50-80% of patients 2, 3
• Avoid legumes, wheat, onions, garlic (oligosaccharides)
• Limit lactose and fructose
• Avoid sorbitol and mannitol (polyols)

Second-Line: Pharmacologic Treatment

Opiate agonists (First-line medication):

• Loperamide: Most effective first-line medication, improves symptoms in 50-80% of patients 2, 4
• Start 2-4 mg as needed or scheduled dosing
• Can escalate to codeine or tincture of opium if loperamide fails 4

Anticholinergics:

• Hyoscyamine or dicyclomine for abdominal cramping
• Effective in 50-80% when combined with other therapies 2

5-HT3 receptor antagonists:

• Ondansetron, alosetron (restricted availability), or ramosetron
• Particularly useful for urgency and frequency 2, 3
• Conditional recommendation due to variable evidence quality

Eluxadoline:

• Mixed opioid receptor modulator
• Strong consensus for use in IBS-D (also applicable to functional diarrhea) 3
• Avoid in patients without gallbladder or with history of pancreatitis

Rifaximin:

• 550 mg three times daily for 14 days
• Strong consensus for IBS-D; may benefit functional diarrhea 3
• Targets gut microbiome dysbiosis

Probiotics:

• Weak/conditional recommendation
• May help regulate gut microbiome 5, 3

Bile acid sequestrants:

• If bile acid diarrhea suspected or confirmed
• Cholestyramine 4g 1-2 times daily or colesevelam 625mg 1-3 tablets twice daily
• Conditional recommendation 3

Third-Line: Neuromodulators

Tricyclic antidepressants:

• For patients with significant abdominal pain component
• Start low dose (10-25 mg at bedtime), titrate slowly
• Weak recommendation 3

Gut-directed psychological therapies:

• Cognitive behavioral therapy
• Strong consensus for refractory cases 3

Critical Pitfalls to Avoid

1. Do not perform extensive parasite testing without travel history—this leads to false positives and unnecessary treatment 1

2. Do not skip celiac testing—this is a strong recommendation with moderate evidence, and missing celiac disease has significant morbidity implications 1

3. Do not use ESR/CRP for IBD screening—fecal calprotectin is superior 1

4. Do not delay empiric bile acid sequestrant trial while waiting for specialized testing that may not be available 1

5. Do not perform colonoscopy in young patients without alarm features—this is low-yield and exposes patients to unnecessary risk 2, 3

Nuances in Evidence

The AGA guidelines 1 acknowledge that most diagnostic studies used case-control designs in tertiary care settings, which inflates sensitivity/specificity estimates. This means real-world test performance may be lower than reported. The guidelines appropriately balance this limitation by making strong recommendations only where evidence is robust (Giardia, celiac testing) and conditional recommendations where evidence is weaker (bile acid testing, fecal inflammatory markers).

The distinction between functional diarrhea and IBS-D is often blurred in clinical practice—functional diarrhea lacks the significant abdominal pain that defines IBS-D. Treatment approaches overlap substantially, though pain-predominant symptoms may respond better to neuromodulators 2, 3.